Refine
Year of publication
Document Type
- Article (5346)
- Doctoral Thesis (1517)
- Part of Periodical (211)
- Conference Proceeding (189)
- Preprint (172)
- Book (86)
- Contribution to a Periodical (69)
- Review (50)
- Working Paper (22)
- Part of a Book (17)
Language
Keywords
- inflammation (81)
- COVID-19 (60)
- SARS-CoV-2 (48)
- apoptosis (39)
- Inflammation (38)
- cancer (38)
- glioblastoma (38)
- breast cancer (34)
- prostate cancer (30)
- autophagy (29)
Institute
- Medizin (7699) (remove)
Background: Both selective mutism (SM) and social anxiety disorder (SAD) are severe pediatric anxiety disorders with the common trait of behavioral inhibition (BI). The underlying pathophysiology of these disorders remains poorly understood, however converging evidence suggests that alterations in several peripheral molecular pathways might be involved. In a pilot study, we investigated alterations in plasma molecular markers (dipeptidyl peptidase-4 [DPPIV], interleukin-6 [IL-6], tumor necrosis factor-β [TNF-β] and neuropeptide-Y [NPY]) in children with SM, SAD, and healthy controls, as well as the correlation of these markers to symptom severity. Methods: We included 51 children and adolescents (aged 5–18 years; n = 29 girls): n = 20 children in the SM-, n = 16 in the SAD- and n = 15 in the control-group (CG). Peripheral blood samples were analyzed for DPPIV, IL-6, TNF-β, and NPY concentrations. Diverse psychometric measures were used for BI, anxiety, and mutism symptoms. Results: Lower DPPIV-levels were correlated with more anxiety symptoms. However, we could not find a difference in any molecular marker between the patients with SAD and SM in comparison to the CG. Conclusion: DPPIV is proposed as relevant marker for child and adolescent anxiety. Investigating the pathophysiology of SM and SAD focusing on state and trait variables as anxiety or BI might help better understanding the underlying mechanisms of these disorders. Further studies with especially larger cohorts are needed to validate the current pilot-findings.
Since the survival rates of pediatric patients undergoing cancer treatment or hematopoietic stem cell transplantation (HSCT) have increased rapidly in recent decades, the late effects of treatment are now an important focus of patient care. Access to fertility preservation (FP) procedures as well as their financing differs considerably across Europe. However, some countries in Europe have recently changed the legal basis for financing FP procedures; therefore, the implementation of structures is mandatory to give patients access to FP. In this prospective cohort study, we characterized the process for establishing pediatric fertility counseling, including the development of an in-house standard procedure for recommendations regarding FP with potentially gonadotoxic treatment and valuating data from all FP counseling sessions. All data concerning patient characteristics (pubertal status, disease group) and recommendation of FP measures were prospectively collected and adoption of FP measures analyzed. Prior to the establishment of a structured process for FP in our pediatric oncology and stem cell transplantation center, there was no standardized FP counseling. We demonstrate that with the establishment of an inhouse standard procedure, it is possible to give consistent yet individualized FP counseling to approximately 90% of our patients facing gonadotoxic treatment, counseling over 200 patients between 2017 and 2019. This pilot study could potentially be adapted in other pediatric hematology, oncology, and stem cell transplantation centers to allow a more standardized handling of FP counseling for all patients facing gonadotoxic treatment.
Purpose: To investigate short-term (3 months follow-up) changes in visual quality following Descemet membrane endothelial keratoplasty (DMEK) for Fuchs endothelial dystrophy (FED). Methods: In this prospective institutional case series, 51 patients that underwent DMEK for FED were included. Assessment included the Quality of Vision (QoV) questionnaire preoperatively, at 1 month, and 3 months after surgery. Secondary outcome measures were anterior segment parameters acquired by Scheimpflug imaging, corrected distance visual acuity (CDVA), and endothelial cell density (ECD). Results: Glare, hazy vision, blurred vision, and daily fluctuation in vision were the symptoms mostly reported preoperatively. All symptoms demonstrated a significant reduction of item scores for severity, frequency, and bothersome in the course after DMEK (P < 0.01). Glare and fluctuation in vision remained to some extent during the follow-up period (median score = 1). Preoperatively, corneal densitometry correlated moderately to weakly with severity of hazy vision (rs = 0.39; P = 0.03) and frequency (rs = 0.26; P = 0.02) as well as severity (rs = 0.27; P = 0.03) of blurry vision. CDVA and central corneal thickness (CCT) did not correlate with visual complains. Conclusions: Following DMEK for FED, patient-reported visual symptoms assessed by the QoV questionnaire represent a useful tool providing valuable information on the impact of DMEK on visual quality that cannot be directly estimated by morphological parameters and visual acuity only.
Background: SAMHD1 mediates resistance to anti-cancer nucleoside analogues, including cytarabine, decitabine, and nelarabine that are commonly used for the treatment of leukaemia, through cleavage of their triphosphorylated forms. Hence, SAMHD1 inhibitors are promising candidates for the sensitisation of leukaemia cells to nucleoside analogue-based therapy. Here, we investigated the effects of the cytosine analogue CNDAC, which has been proposed to be a SAMHD1 inhibitor, in the context of SAMHD1. Methods: CNDAC was tested in 13 acute myeloid leukaemia (AML) cell lines, in 26 acute lymphoblastic leukaemia (ALL) cell lines, ten AML sublines adapted to various antileukaemic drugs, 24 single cell-derived clonal AML sublines, and primary leukaemic blasts from 24 AML patients. Moreover, 24 CNDAC-resistant sublines of the AML cell lines HL-60 and PL-21 were established. The SAMHD1 gene was disrupted using CRISPR/Cas9 and SAMHD1 depleted using RNAi, and the viral Vpx protein. Forced DCK expression was achieved by lentiviral transduction. SAMHD1 promoter methylation was determined by PCR after treatment of genomic DNA with the methylation-sensitive HpaII endonuclease. Nucleoside (analogue) triphosphate levels were determined by LC-MS/MS. CNDAC interaction with SAMHD1 was analysed by an enzymatic assay and by crystallisation. Results: Although the cytosine analogue CNDAC was anticipated to inhibit SAMHD1, SAMHD1 mediated intrinsic CNDAC resistance in leukaemia cells. Accordingly, SAMHD1 depletion increased CNDAC triphosphate (CNDAC-TP) levels and CNDAC toxicity. Enzymatic assays and crystallisation studies confirmed CNDAC-TP to be a SAMHD1 substrate. In 24 CNDAC-adapted acute myeloid leukaemia (AML) sublines, resistance was driven by DCK (catalyses initial nucleoside phosphorylation) loss. CNDAC-adapted sublines displayed cross-resistance only to other DCK substrates (e.g. cytarabine, decitabine). Cell lines adapted to drugs not affected by DCK or SAMHD1 remained CNDAC sensitive. In cytarabine-adapted AML cells, increased SAMHD1 and reduced DCK levels contributed to cytarabine and CNDAC resistance. Conclusion: Intrinsic and acquired resistance to CNDAC and related nucleoside analogues are driven by different mechanisms. The lack of cross-resistance between SAMHD1/ DCK substrates and non-substrates provides scope for next-line therapies after treatment failure.
Cancer therapies have experienced significant advances in recent years. While conventional cytotoxic chemotherapy has long been the cornerstone for the treatment of many tumor entities, uprising immunotherapies have revolutionized the therapeutic landscape. Among them, immune checkpoint inhibitors (ICIs) with their demonstrated increased overall survival rates and response rates in cancer patients are now FDA-approved for metastatic melanoma and multiple other malignancies. Despite their clinical benefit in cancer therapies, ICIs can induce unique autoimmune-like toxicities known as immune-related adverse events (irAEs), which can involve any organ system including the nervous system. Although neurotoxicities are rare complications of ICI therapy they are often severe and can lead to long-term disability or even death if left untreated.
Neurological irAEs exhibit a broad spectrum of clinical presentations affecting the entire nervous system. Diagnosing neurological irAEs is often challenging as symptoms and laboratory findings can be uncharacteristic for common neurological disorders and clinical experience with ICI-mediated toxicities is still limited. In light of expanding clinical indications for ICIs, physicians will encounter ICI-mediated neurotoxicities more frequently. Thus, thorough characterizations of the diverse set of neurological irAEs are essential for optimal patient care, the prevention of severe ICI-mediated complications, and the development of diagnostic and therapeutic algorithms. This work portrays the clinical presentation, management and outcome of neurological irAEs following ICI therapies.
Patients with neurotoxicities related to ICIs who presented at the Yale New Haven Hospital between January 2014 and June 2018 were retrospectively identified from the quality control database. A comprehensive chart review was performed and data regarding patient demographics, medical history, ICI regimen and neurotoxicity were recorded. In total, 18 patients with neurological irAEs following ICI therapy for melanoma, small cell lung cancer, non-small cell lung cancer, and Merkel-cell carcinoma were identified. Neurotoxicities included central nervous system disorders comprising central demyelinating disorder,autoimmune encephalitis predominantly affecting the grey matter, and aseptic meningitis. Peripheral nervous system toxicities included sensorimotor polyneuropathy and myasthenia gravis. Cases of hypophysitis were also recorded. Time to onset of neurological irAEs ranged from 1 to72 weeks with a median of five weeks. In all patients ICIs were held and steroids initiated. Additional immunomodulatory therapies were required in nine patients. Sixteen of 18 patients showed neurological improvement. Fourteen patients had highgrade neurotoxicity (grade 3-4), six of whom deceased due to cancer progression, while none of the low-grade neurotoxicity patients (grade 1-2) died. High-grade neurotoxicity was identified as a negative prognostic marker for overall survival (p = 0.046).
This work shows that neurotoxicities present early-onset, rapidly progressive complications of ICIs with a broad spectrum of clinical phenotypes affecting the central nervous system, peripheral nervous system, and neuroendocrine system. A high index of caution for neurological irAEs is warranted throughout ICI therapy as timely diagnosis and management can reduce morbidity and mortality. Randomized clinical trials are needed to develop standardized diagnostic and therapeutic algorithms of ICI-induced neurotoxicities.
Eines der übergeordneten Ziele neurowissenschaftlicher Grundlagenforschung ist es, die Pathomechanismen neuropsychiatrischer Erkrankungsbilder besser zu verstehen. Als Erklärungsmodell für einige dieser Erkrankungen dient unter anderem ein gestörtes Verhältnis zwischen Exzitation und Inhibition im Gehirn. Synaptische Strukturproteine sind wichtige Modulatoren dieses Verhältnisses. Für eine unbeeinträchtigte inhibitorische synaptische Transmission spielt das postsynaptische Zelladhäsionsprotein Neuroligin 2 eine maßgebliche Rolle, um das Gleichgewicht zwischen Exzitation und Inhibition aufrechtzuerhalten. Neuroligin 2 ist an der inhibitorischen Synapse lokalisiert und beeinflusst die Entwicklung, Reifung und Funktion dieser Synapse. Die klinische Relevanz von Neuroligin 2 wurde bereits bei zahlreichen Erkrankungsbildern wie Schizophrenie, Depression oder Epilepsie im Rahmen von Studien nachgewiesen. Um das Verhältnis zwischen Exzitation und Inhibition in vivo sowie Mechanismen der synaptischen Übertragung und Plastizität zu untersuchen, hat sich die Ableitung von Feldpotentialen im Gyrus Dentatus des Hippocampus etabliert. Im Neuroligin 2 Knockout Mausmodell konnte bereits gezeigt werden, dass eine pränatale Deletion dieses Proteins eine stark erhöhte Erregbarkeit der Körnerzellen und eine verminderte GABAerge Netzwerkinhibition im Gyrus Dentatus in vivo zur Folge hat.
Unklar blieb bisher, ob diese durch den konventionellen Neuroligin 2 Knockout (pränatal) hervorgerufenen Netzwerkveränderungen alleine auf das Fehlen dieses Proteins zurückzuführen sind oder durch eine zusätzliche Beeinträchtigung der Hirnentwicklung hervorgerufen werden. Ziel dieser Dissertation ist es deshalb, die Rolle von Neuroligin 2 im Gyrus Dentatus durch einen induzierten Knockout in adulten Mäusen (postnatal) unabhängig von einem möglichen Entwicklungseffekt zu klären.
Dazu wurde im ersten methodischen Schritt dieser Dissertation durch orale Tamoxifen-Gabe eine zeitspezifische konditionale Eliminierung von Neuroligin 2 in genetisch modifizierten, adulten Mäusen erzielt. Im Anschluss an diese konditionale Eliminierung wurde die synaptische Transmission, Plastizität sowie neuronale Erregbarkeit von Körnerzellen im Gyrus Dentatus mittels elektrophysiologischer Experimente untersucht. Hierzu wurde zunächst der Tractus Perforans und die Körnerzellschicht durch stereotaktische Chirurgie in anästhesierten Mäusen lokalisiert. Anschließend wurde eine Stimulation des Tractus Perforans sowie eine Ableitung von Feldpotentialen im Gyrus Dentatus durchgeführt. Um die Erregbarkeit der Körnerzellen, die synaptische Transmission, Kurz- und Langzeitplastizität sowie Netzwerkinhibition im Gyrus Dentatus zu analysieren, wurden unterschiedliche Stimulationsprotokolle verwendet. Im Anschluss an die elektrophysiologischen Experimente wurden die Hippocampi beidseitig entnommen, konserviert und später einer Proteinquantifizierung von Neuroligin 2 mittels Western-Blotting unterzogen.
Die Ergebnisse zeigten ein signifikant verringertes Proteinlevel von Neuroligin 2 auf 41,07% im Hippocampus von konditionalen Neuroligin 2 Knockout Mäusen. Unter dieser Reduktion von Neuroligin 2 in adulten Mäusen war die in vivo Erregbarkeit der Körnerzellen des Gyrus Dentatus sowie GABAerge Netzwerkinhibition weitgehend unbeeinträchtigt und die signifikanten Beobachtungen des konventionellen Knockout Modells ließen sich nicht reproduzieren. Aufgrund der unvollständigen Proteinreduktion lässt sich jedoch nicht abschließend beurteilen, ob die Restmenge den elektrophysiologischen Effekt kompensiert oder ob die im konventionellen Neuroligin 2 Knockout Modell beobachteten Effekte auf eine ausschließliche Rolle von Neuroligin 2 in der Hirnentwicklungsperiode zurückzuführen sind. Kürzlich veröffentlichte Daten zeigten allerdings, dass die postnatale Deletion von Neuroligin 2 in anderen Hirnregionen zu einer verminderten Netzwerkinhibition führt.
Neben der hier verwendeten in vivo Methodik ist eine Ergänzung von Untersuchungen in nicht-anästhesierten Tieren sowie Messungen einzelner Zellen durch whole-cell patch-clamp Untersuchungen in vitro oder in vivo zu erwägen. Es sollte dabei auf eine konditionale Proteineliminierung geachtet werden, damit mögliche Kompensationsmechanismen weitgehend ausgeschlossen werden können. Eine weiterführende immunhistochemische Bildgebung der Hippocampuspräparate, wie sie im konventionellen Knockout durchgeführt wurde, könnte sich hierbei ebenso als aufschlussreich für die Funktion von Neuroligin 2 im Hippocampus des adulten Tieres erweisen.
Transcatheter left atrial appendage occlusion (LAAO) is non-inferior to vitamin K antagonists (VKAs) in preventing thromboembolic events in atrial fibrillation (AF). Non-vitamin K antagonists (NOACs) have an improved safety profile over VKAs; however, evidence regarding their effect on cardiovascular and neurological outcomes relative to LAAO is limited. Up-to-date randomized trials or propensity-score-matched data comparing LAAO vs. NOACs in high-risk patients with AF were pooled in our study. A total of 2849 AF patients (LAAO: 1368, NOACs: 1481, mean age: 75 ± 7.5 yrs, 63.5% male) were enrolled. The mean CHA2DS2-VASc score was 4.3 ± 1.7, and the mean HAS-BLED score was 3.4 ± 1.2. The baseline characteristics were comparable between the two groups. In the LAAO group, the success rate of device implantation was 98.8%. During a mean follow-up of 2 years, as compared with NOACs, LAAO was associated with a significant reduction of ISTH major bleeding (p = 0.0002). There were no significant differences in terms of ischemic stroke (p = 0.61), ischemic stroke/thromboembolism (p = 0.63), ISTH major and clinically relevant minor bleeding (p = 0.73), cardiovascular death (p = 0.63), and all-cause mortality (p = 0.71). There was a trend toward reduction of combined major cardiovascular and neurological endpoints in the LAAO group (OR: 0.84, 95% CI: 0.64–1.11, p = 0.12). In conclusion, for high-risk AF patients, LAAO is associated with a significant reduction of ISTH major bleeding without increased ischemic events, as compared to “contemporary NOACs”. The present data show the superior role of LAAO over NOACs among high-risk AF patients in terms of reduction of major bleeding; however, more randomized controlled trials are warranted.
Simple Summary: The role of transcriptionally deregulated miRNAs (microRNAs) in classical Hodgkin lymphoma (cHL) is still not fully understood. To address this issue, we have performed global miRNA expression profiling of commonly used cHL cell lines and we present a complete cHL miRNome (microRNome). Within this group, we identify miRNAs recurrently deregulated in cHL cell lines, and compare them to non-Hodgkin lymphoma cell lines and sorted normal CD77+ germinal centre B-cells. Moreover, we show that several of the recurrently overexpressed miRNAs in cHL cell lines, and also primary microdissected HRS (Hodgkin and Reed-Sternberg) cells, target known B-cell-related transcription factors and NF-κB inhibitors. These findings provide evidence that deregulated miRNAs contribute to the loss of B-cell phenotype and NF-κB activation observed in this lymphoma.
Abstract: A hallmark of classical Hodgkin lymphoma (cHL) is the attenuation of B-cell transcription factors leading to global transcriptional reprogramming. The role of miRNAs (microRNAs) involved in this process is poorly studied. Therefore, we performed global miRNA expression profiling using RNA-seq on commonly used cHL cell lines, non-Hodgkin lymphoma cell lines and sorted normal CD77+ germinal centre B-cells as controls and characterized the cHL miRNome (microRNome). Among the 298 miRNAs expressed in cHL, 56 were significantly overexpressed and 23 downregulated (p < 0.05) compared to the controls. Moreover, we identified five miRNAs (hsa-miR-9-5p, hsa-miR-24-3p, hsa-miR-196a-5p, hsa-miR-21-5p, hsa-miR-155-5p) as especially important in the pathogenesis of this lymphoma. Target genes of the overexpressed miRNAs in cHL were significantly enriched (p < 0.05) in gene ontologies related to transcription factor activity. Therefore, we further focused on selected interactions with the SPI1 and ELF1 transcription factors attenuated in cHL and the NF-ĸB inhibitor TNFAIP3. We confirmed the interactions between hsa-miR-27a-5p:SPI1, hsa-miR-330-3p:ELF-1, hsa-miR-450b-5p:ELF-1 and hsa-miR-23a-3p:TNFAIP3, which suggest that overexpression of these miRNAs contributes to silencing of the respective genes. Moreover, by analyzing microdissected HRS cells, we demonstrated that these miRNAs are also overexpressed in primary tumor cells. Therefore, these miRNAs play a role in silencing the B-cell phenotype in cHL.
Introduction: Cancer patients tend to prefer oral instead of parenteral chemotherapy. To date, there is little evidence on the medication adherence in cancer patients. We investigated medication adherence to tyrosine kinase inhibitors in patients suffering from non-small cell lung cancer. Methods: Tyrosine kinase inhibitor adherence was measured electronically by MEMS® (medication event monitoring system) over at least six months. Adherence rates were calculated in terms of Dosing Compliance, Timing Compliance, Taking Compliance, and Drug Holidays. Patients were dichotomized as adherent when Dosing Compliance and Timing Compliance were ≥80%, Taking Compliance ranged between 90 and 110%, and <1 Drug Holiday was registered. Quality of life was assessed by two questionnaires (EORTC QLQ-C30 version 3.0, EORTC QLQ-LC13) at three time points. Adverse drug events were reported via patient diaries. Results: Out of 32 patients enrolled, data from 23 patients were evaluable. Median Dosing Compliance, Taking Compliance, and Timing Compliance adherence rates of tyrosine kinase inhibitor intake amounted to 100%, 98%, and 99%, respectively; Drug Holidays were observed in three patients. Four patients were dichotomized as non-adherent. Three of them had a twice-daily tyrosine kinase inhibitor regimen. Median quality of life scores amounted to 67 (max. 100) and remained unchanged over the study period. Fatigue and rash were the most frequently reported adverse drug events. Conclusion: Medication adherence of non-small cell lung cancer patients treated with tyrosine kinase inhibitors was extraordinarily high and is likely to support the effectiveness of tyrosine kinase inhibitor treatment and a good quality of life over a long period of time. Adherence facilitating information and education is especially relevant for patients taking tyrosine kinase inhibitors in a twice-daily regimen.
Preeclampsia (PE), a gestational hypertensive disease originating from the placenta, is characterized by an imbalance of various cellular processes. The cell cycle regulator p21Cip1/CDKN1A (p21) and its family members p27 and p57 regulate signaling pathways fundamental to placental development. The aim of the present study was to enlighten the individual roles of these cell cycle regulators in placental development and their molecular involvement in the pathogenesis of PE. The expression and localization of p21, phospho-p21 (Thr-145), p27, and p57 was immunohistochemically analyzed in placental tissues from patients with early-onset PE, early-onset PE complicated by the HELLP (hemolysis, elevated liver enzymes and low platelet count) syndrome as well as late-onset PE compared to their corresponding control tissues from well-matched women undergoing caesarean sections. The gene level was evaluated using real-time quantitative PCR. We demonstrate that the delivery mode strongly influenced placental gene expression, especially for CDKN1A (p21) and CDKN1B (p27), which were significantly upregulated in response to labor. Cell cycle regulators were highly expressed in first trimester placentas and impacted by hypoxic conditions. In support of these observations, p21 protein was abundant in trophoblast organoids and hypoxia reduced its gene expression. Microarray analysis of the trophoblastic BeWo cell line depleted of p21 revealed various interesting candidate genes and signaling pathways for the fusion process. The level of p21 was reduced in fusing cytotrophoblasts in early-onset PE placentas and depletion of p21 led to reduced expression of fusion-related genes such as syncytin-2 and human chorionic gonadotropin (β-hCG), which adversely affected the fusion capability of trophoblastic cells. These data highlight that cell cycle regulators are important for the development of the placenta. Interfering with p21 influences multiple pathways related to the pathogenesis of PE.
Although anti-cancer properties of the natural compound curcumin have been reported, low absorption and rapid metabolisation limit clinical use. The present study investigated whether irradiation with visible light may enhance the inhibitory effects of low-dosed curcumin on prostate cancer cell growth, proliferation, and metastasis in vitro. DU145 and PC3 cells were incubated with low-dosed curcumin (0.1–0.4 µg/mL) and subsequently irradiated with 1.65 J/cm2 visible light for 5 min. Controls remained untreated and/or non-irradiated. Cell growth, proliferation, apoptosis, adhesion, and chemotaxis were evaluated, as was cell cycle regulating protein expression (CDK, Cyclins), and integrins of the α- and β-family. Curcumin or light alone did not cause any significant effects on tumor growth, proliferation, or metastasis. However, curcumin combined with light irradiation significantly suppressed tumor growth, adhesion, and migration. Phosphorylation of CDK1 decreased and expression of the counter-receptors cyclin A and B was diminished. Integrin α and β subtypes were also reduced, compared to controls. Irradiation distinctly enhances the anti-tumor potential of curcumin in vitro and may hold promise in treating prostate cancer.
The aim of this study was to evaluate whether recurrent carpal tunnel syndrome (CTS) after complete and sufficient division of the transverse ligament really exists. Another goal was to analyze the underlying reasons for recurrent CTS operated on in our department. Over an observation period of eleven years, 156 patients underwent surgical intervention due to CTS. The records of each patient were analyzed with respect to baseline data (age, gender, affected hand), as were clinical signs and symptoms pre- and postoperatively. To assess long-term results, standardized telephone interviews were performed using a structured questionnaire in which the patients were questioned about persisting symptoms, if any. Of the 156 patients, 128 underwent first surgical intervention due to CTS in our department. In long-term follow-up, two-thirds of these patients had no symptoms at all; one-third of the patients described mild persisting numbness. None of the patients experienced a recurrence of CTS. The 28 patients who received their first operation outside of our department were operated on for recurrent CTS. The cause of recurrence was incomplete division of the distal part of the transverse carpal ligament in all cases. The results suggest that recurrent CTS after complete and sufficient division of the transverse ligament is very unlikely.
Background: Dentists (Ds) and dental assistants (DAs) have a high lifetime prevalence of musculoskeletal disorders (MSDs). In this context, it is assumed that they have an increased intake of substances such as pain medication. Currently, there exist no data on the use of medication among Ds and DAs with MSDs in Germany. Methods: The online questionnaire (i.e., the Nordic Questionnaire) analysed the medical therapies used by 389 Ds (240 f/149 m) and 406 DAs (401 f/5 m) to treat their MSDs. Results: Ds (28.3–11.5%) and DAs (29.4–10.3%) with MSDs took medication depending on the affected body region. A trend between the Ds and DAs in the intake of drug therapy and the frequency was found for the neck region (Ds: 21.1%, DAs: 28.7%). A single medication was taken most frequently (Ds: 60.0–33.3%, DAs: 71.4–27.3%). The frequency of use varied greatly for both occupational groups depending on the region affected. Conclusion: Ds and DAs perceived the need for medical therapies because of their MSDs. Painkillers such as ibuprofen and systemic diclofenac were the medications most frequently taken by both occupational groups. The intake of pain killers, most notably for the neck, should prevent sick leave.
Sphingosine 1 phosphate (S1P) lyase (Sgpl1) catalyses the irreversible cleavage of S1P and thereby the last step of sphingolipid degradation. Loss of Sgpl1 in humans and mice leads to accumulation of sphingolipids and multiple organ injuries. Here, we addressed the role of hepatocyte Sgpl1 for regulation of sphingolipid homoeostasis by generating mice with hepatocyte-specific deletion of Sgpl1 (Sgpl1HepKO mice). Sgpl1HepKO mice had normal body weight, liver weight, liver structure and liver enzymes both at the age of 8 weeks and 8 months. S1P, sphingosine and ceramides, but not glucosylceramides or sphingomyelin, were elevated by ~1.5–2-fold in liver, and this phenotype did not progress with age. Several ceramides were elevated in plasma, while plasma S1P was normal. Interestingly, S1P and glucosylceramides, but not ceramides, were elevated in bile of Sgpl1HepKO mice. Furthermore, liver cholesterol was elevated, while LDL cholesterol decreased in 8-month-old mice. In agreement, the LDL receptor was upregulated, suggesting enhanced uptake of LDL cholesterol. Expression of peroxisome proliferator-activated receptor-γ, liver X receptor and fatty acid synthase was unaltered. These data show that mouse hepatocytes largely compensate the loss of Sgpl1 by secretion of accumulating sphingolipids in a specific manner into blood and bile, so that they can be excreted or degraded elsewhere.
Objective: Dravet syndrome (DS) is a rare but severe drug-resistant epilepsy. Before the approval of fenfluramine (FFA) for the treatment of seizures in DS, patients in Germany could receive treatment under a compassionate use program (CUP). Methods: We conducted a multicenter, retrospective, observational study to describe the efficacy, tolerability, and retention of FFA within the CUP. Patients received add-on therapy with oral FFA gradually titrated to a target dose between .13 and .7 mg/kg/day Results: Overall, 78 patients with DS (median age = 8.0 years, range = 2.1–46.0; 53% female, median concomitant antiseizure medications [ASMs] = 3) were treated with FFA for a median duration of 255.5 days (range = 31–572). Responder rates (a ≥50% reduction; n = 78) and seizure-freedom rates at 3 months were 68% and 14% for total seizures, respectively, and 67% and 23% for generalized tonic–clonic seizures. Responder rates were consistent at 6 and 12 months (n = 66 and n = 43, respectively). Median seizure days per month significantly decreased from 10.0 (range = .5–30) to 3.0 (range = 0–30) in the 3-month period before and after FFA treatment (p < .001). Significantly fewer patients reported at least one episode of status epilepticus (28% vs. 14% patients before and after FFA initiation, p = .005). During FFA treatment, 35 (45%) patients were able to discontinue a concomitant ASM. At the last follow-up date, 66 (85%) patients remained on treatment with FFA. The most common adverse events were somnolence (36%), decreased appetite (22%), and ataxia (8%). Forty-eight (62%) patients were reported as having a meaningful global clinical improvement. Significance: In a large cohort of patients, FFA demonstrated efficacy across a range of outcomes including clinically significant reductions in convulsive seizures, and was well tolerated, providing valuable information for real-world practice.
Objective: Dravet syndrome (DS) is a rare but severe drug-resistant epilepsy. Before the approval of fenfluramine (FFA) for the treatment of seizures in DS, patients in Germany could receive treatment under a compassionate use program (CUP). Methods: We conducted a multicenter, retrospective, observational study to describe the efficacy, tolerability, and retention of FFA within the CUP. Patients received add-on therapy with oral FFA gradually titrated to a target dose between .13 and .7 mg/kg/day. Results: Overall, 78 patients with DS (median age = 8.0 years, range = 2.1–46.0; 53% female, median concomitant antiseizure medications [ASMs] = 3) were treated with FFA for a median duration of 255.5 days (range = 31–572). Responder rates (a ≥50% reduction; n = 78) and seizure-freedom rates at 3 months were 68% and 14% for total seizures, respectively, and 67% and 23% for generalized tonic–clonic seizures. Responder rates were consistent at 6 and 12 months (n = 66 and n = 43, respectively). Median seizure days per month significantly decreased from 10.0 (range = .5–30) to 3.0 (range = 0–30) in the 3-month period before and after FFA treatment (p < .001). Significantly fewer patients reported at least one episode of status epilepticus (28% vs. 14% patients before and after FFA initiation, p = .005). During FFA treatment, 35 (45%) patients were able to discontinue a concomitant ASM. At the last follow-up date, 66 (85%) patients remained on treatment with FFA. The most common adverse events were somnolence (36%), decreased appetite (22%), and ataxia (8%). Forty-eight (62%) patients were reported as having a meaningful global clinical improvement. Significance: In a large cohort of patients, FFA demonstrated efficacy across a range of outcomes including clinically significant reductions in convulsive seizures, and was well tolerated, providing valuable information for real-world practice.
Key Points: Seventy-eight patients with Dravet syndrome were treated with FFA at multiple centers within the CUP in Germany; FFA had a good retention rate over a sustained period; 85% of patients remained on treatment with FFA for a median duration of 255.5 days; FFA was associated with clinically meaningful reductions in total and convulsive seizures, seizure days per month, and episodes of status epilepticus; FFA was associated with reductions in the number or dose of concomitant antiseizure medications in 68% of patients; FFA was well tolerated, with the main adverse events being somnolence (36%), decreased appetite (22%), and ataxia (8%).
Background: To test the effect of urological primary cancers (bladder, kidney, testis, upper tract, penile, urethral) on overall mortality (OM) after secondary prostate cancer (PCa). Methods: Within the Surveillance, Epidemiology and End Results (SEER) database, patients with urological primary cancers and concomitant secondary PCa (diagnosed 2004-2016) were identified and were matched in 1:4 fashion with primary PCa controls. OM was compared between secondary and primary PCa patients and stratified according to primary urological cancer type, as well as to time interval between primary urological cancer versus secondary PCa diagnoses. Results: We identified 5,987 patients with primary urological and secondary PCa (bladder, n = 3,287; kidney, n = 2,127; testis, n = 391; upper tract, n = 125; penile, n = 47; urethral, n = 10) versus 531,732 primary PCa patients. Except for small proportions of Gleason grade group and age at diagnosis, PCa characteristics between secondary and primary PCa were comparable. Conversely, proportions of secondary PCa patients which received radical prostatectomy were smaller (29.0 vs. 33.5%), while no local treatment rates were higher (34.2 vs. 26.3%). After 1:4 matching, secondary PCa patients exhibited worse OM than primary PCa patients, except for primary testis cancer. Here, no OM differences were recorded. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis. Conclusions: After detailed matching for PCa characteristics, secondary PCa patients exhibit worse survival, except for testis cancer patients. The survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary urological cancer diagnosis.
Im Bereich der Neonatologie kommen die Patient*innen oft multimorbide zu Welt oder sind für bestimmte Komplikationen gefährdet, die sich aus ihrer Unreife ergeben. Dabei spielen sowohl bei reifen kranken Neugeborenen und erst recht bei Frühgeborenen Erkrankungen der Atemwege eine Hauptrolle. Nach wie vor ist das konventionelle Röntgen in diesem Bereich der Medizin ein wichtiges Instrument. Die diagnostische Strahlenexposition bietet jedoch immer wieder Raum zur Diskussion. Die Patient*innen sind nur wenige Tage alt und besitzen somit über eine hohe Proliferationsrate und ein Maß an undifferenzierten Zellen, sie erhalten in Summe teilweise viele Aufnahmen und haben auf der anderen Seite eine hohe Lebenserwartung, wenn sie die Neugeborenenzeit ohne Komplikationen überleben. Haupteffekte ionisierender Strahlen sind für die Früh- und kranken Neugeborenen Malignome, vor allem die Leukämien. Es soll herausgefunden werden, inwieweit die Strahlenbelastung ein gesundheitliches Risiko für die Früh- und Neugeborenen darstellt.
Hintergrund: Gegenstand der wissenschaftlichen und klinischen Diskussion ist immer wieder das eventuell bestehende Risiko der einfallenden ionisierenden Röntgenstrahlung auf das Früh- oder Neugeborene, dennoch ist das Röntgen als diagnostisches Mittel notwendig. Es soll untersucht werden, wie hoch das gesundheitliche Risiko durch diagnostische Röntgenaufnahmen in der Praxis für die Früh- und Neugeborenen ist.
Material und Methoden: Alle Patient*innen des Schwerpunktes Neonatologie in der Klinik für Kinder- und Jugendmedizin aus dem Zeitraum vom 01.01.2013 bis 31.12.2018 im Universitätsklinikum Frankfurt wurden retrospektiv untersucht. Es wurden die Anzahl der Röntgenaufnahmen pro Patient*in, die zugrunde liegende Indikation, das Dosisflächenprodukt (DFP), die Effektive Dosis (ED) und das geschätzte Risiko dokumentiert, bzw. errechnet. Die ED ist eine Schätzgröße, welche mittels Konversionskoeffizienten aus den Eingangsgrößen des DFP, der Eintrittsdosis oder dem Air Kerma (Kai) berechnet wird. Im ICRP Bericht Nr. 60 finden sich Faktoren zur Risikoabschätzung von 2,8 bis 13*10-2 Sv-1. Diese Risikoeinschätzung nähert das durch Strahlung induzierte Risiko für Krebs in der ersten Lebensdekade an – vor allem für Leukämien, aber auch andere Krebsarten.
Ergebnisse: Von den insgesamt 3843 stationär in der Neonatologie behandelten Patient*innen (2013-2018) erhielten 1307 (34%) mindestens eine Röntgenaufnahme. Pro Jahr wurden in einer Abteilung für Neonatologie ca. 700 Röntgenaufnahmen angefertigt. Die mittlere Anzahl an Röntgenaufnahmen pro Patient*in betrug 3,19 Aufnahmen und korrelierte gegensinnig mit Geburtsgewicht und Gestationsalter. Am häufigsten wurden sehr kleine Frühgeborene untersucht, meistens in den ersten drei Lebenstagen. Im Laufe des Beobachtungszeitraums wurden weniger Röntgenaufnahmen angefertigt. Die häufigsten Gründe für Röntgenaufnahmen waren Kontrollen von Tubus oder ZVK-Lage. Je reifer und schwerer die Neugeborenen waren, desto seltener wurde ein pathologischer Befund erhoben. Bei niedrigem Geburtsgewicht war die Thoraxabdomenaufnahme die bevorzugte Röntgenart, bei reiferen Patient*innen die Thoraxaufnahme. Das kumulative DFP betrug im Mittel 5,95 mGy*cm² und die kumulative ED betrug im Mittel 23,7 µSv pro Aufenthalt. Damit errechnete sich ein Risiko von 3,1*10-6, das bedeutet 3,1 von 1.000.000 Patient*innen entwickeln nach dieser kumulativen Strahlendosis in der ersten Lebensdekade womöglich Krebs. Das kumulative DFP und die ED pro Aufenthalt und somit auch das Risiko, nach einer gewissen Strahlenexposition Krebs zu entwickeln, sinken mit zunehmendem Geburtsgewicht und zeigen einen Höhepunkt bei einem Geburtsgewicht von <500 g. Die maximale kumulative Strahlendosis betrug 342 µSv mit einem daraus resultierenden Risiko von 44*10-6 und ist damit selbst bei diesem Patienten nach Martin et al. als „minimal“ zu werten.
Schlussfolgerung: Die Strahlenbelastung der Früh- und Neugeborenen konnte evaluiert werden und der Zusammenhang zwischen Unreife und Strahlenbelastung konnte bestätigt werden. Die Strahlenbelastung fiel im internationalen Vergleich minimal aus und es ist nicht von einem gesundheitlichen Risiko durch diagnostische Bildgebung auszugehen. Dies lässt sich vor allem durch moderne Technik mit kurzer Belichtungszeit und hoher Aufnahmespannungen und durch die relativ niedrige Anzahl an gemachten Röntgenbildern erklären. Da bei weiterer Minimierung der eingesetzten Dosis von einem Qualitätsverlust der Bilder auszugehen ist, ist die Einsparung von Röntgenuntersuchungen und die vermehrte Nutzung von Alternativen anzuraten. Die Indikationen müssen vor allem bei Patient*innen <500 g genauestens überprüft werden. Weiterhin sollte nach Alternativen (Sonographie, Kernspintomographie) gesucht werden.
Increased intraindividual variability of reaction time is a main cognitive feature of Attention Deficit Hyperactivity Disorder. It is associated with deficits in sustained attention. While traditionally, mean and variance were used to characterize reaction time distributions, the ex-gaussian distributional model allows a more sophisticated analysis of reaction time series. Reaction time distributions are separated in a normal and an exponential component.
The present study investigates the impact of incentives on reaction time variability in a sample of adult ADHD patients. ADHD is associated with increased Tau, the output parameter of the ex-gaussian model characterizing the exponential part of the distribution. Tau is linked to “lapses of attention”, which are more frequent in ADHD patients. It is known that tau can be modulated in ADHD Patients. It was therefore postulated that tau would be higher in ADHD Patients in a paradigm where quick answers were required but could be modulated by monetary incentives. In addition, the effect of “delay discounting”, which is more distinct in ADHD patients, on reaction time variability was investigated. Eventually, the association of variability measures with strength of ADHD symptoms was tested.
To this end, reaction time distributions of 62 adult ADHD patients and 45 healthy controls from two different reaction time paradigms were analyzed. The monetary incentive delay task, by comprehending a control – and a win condition, allows an investigation of the effect of incentives on reaction times. Subjects had to react as fast as possible by keypress to a stimulus, after a cue signaled a possible monetary reward. During the Delay-Discounting-Task, subjects had to choose between sooner, but smaller, and higher delayed monetary rewards, during which they could use as much time for consideration as desired.
Results show that an increased Tau in the control condition of the monetary- incentive-delay-task could be replicated, while a distinct influence of the win condition emerged. Subjects with ADHD showed an improvement of Tau in the win condition even below the level of healthy controls. However, they showed increased variability of the “regular” responses around the mean of the normal component of the distribution, represented by sigma. Moreover, it was indicated by trend a higher reaction time variability in ADHD patients during choices of delayed rewards. Tau was associated the current symptom strength as well as with the strength of ADHD-Symptoms during childhood, assessed by questionnaire.
While the present results could have implications for etiological models of the disease, they may also contribute to the development of novel diagnostic methods. In advanced studies, neural correlates of sophisticated measures of reaction time variability should be investigated. Furthermore, they should be associated with genetic risk factors with regard to possible endophenotypes. Possible implications for clinical handling of patients should be explored.
Hintergrund: Die Verankerung der Kompetenzorientierung und die Betonung der praktisch-klinischen Ausbildung im Rahmen des Medizinstudiums sind zentrale Punkte in den Neuerungen der Ärztlichen Approbationsordnung. Mit der Entwicklung des Nationalen Kompetenzbasierten Lernzielkatalogs Medizin (NKLM) ist ein Rahmenwerk erstellt und verabschiedet worden, das die Inhalte des gesamten Medizinstudiums in Deutschland abbilden und eine Implementierung kompetenzorientierter Lernziele an den Fakultäten forcieren soll. Um diesem Ziel gerecht zu werden, müssen bereits an den Fakultäten vorhandene Lehrveranstaltungen mit dem NKLM abgeglichen und im Rahmen eines Curriculum Mappings kartiert werden. Ziel der vorliegenden Arbeit ist daher die Kartierung der im Frankfurter Blockpraktikum Chirurgie erlernten Kompetenzen im Sinne eines Curriculum Mappings in Anlehnung an die im NKLM formulierten Lernziele. Zudem wurde folgenden Fragestellungen nachgegangen: Welcher Umfang kompetenzorientierter Lernziele kann Studierenden in einem zweiwöchigen Praktikum Chirurgie vermittelt werden? Wie ist die Vermittlung der einzelnen Kapitel des NKLM im Blockpraktikum Chirurgie gewichtet? Gibt es Unterschiede der erreichten Lernziele in Abhängigkeit des Geschlechts der Studierenden, der besuchten Fachrichtung bzw. des besuchten Lehrkrankenhauses?
Material und Methoden: Im Rahmen der vorliegenden Arbeit wurden Medizinstudierende im zweiten bzw. dritten klinischen Semester unmittelbar nach Abschluss ihres Blockpraktikums Chirurgie gebeten, unter Nutzung eines Online-Fragebogens anzugeben, welche der im NKLM formulierten Lernziele sie im zweiwöchigen Blockpraktikum Chirurgie gelernt haben. Somit konnte für jedes Kapitel dargestellt werden, zu welchem prozentualen Anteil die Lernziele dieses Kapitels erreicht worden sind. Zudem wurden die soziodemographischen Daten der Studierenden, die Fachrichtung des Blockpraktikums und das Lehrkrankenhaus erfasst. Die statistische Auswertung erfolgte mit dem Wilcoxon-Mann-Whitney Test und dem Kruskal-Wallis Test.
Ergebnisse: Insgesamt nahmen 81 Studierenden (28 Männer, 53 Frauen) aus dem 2. bzw 3. klinischen Semester an der Studie teil. Insgesamt wurden im zweiwöchigen Blockpraktikum Chirurgie 8,78 ± 5,10% (Min. 1,01%; Max. 29,84%) aller Lernziele von den Studierenden erreicht. Hierbei wurden anteilig die meisten Lernziele in den Kapiteln 5-11 (Abschnitt 1 „Ärztliche Rollen“) mit 29,92 ± 15,22% (Min. 0,00%; Max. 63,10%) vermittelt. Aus Abschnitt 2 („Medizinisches Wissen, klinische Fähigkeiten und professionelle Haltungen“) wurden vor allem die Lernziele der Kapitel 14b „Klinisch-praktische Fertigkeiten“ (15,49 ± 7,78% (Min. 0,00%; Max. 41,30%) und 14c „Ärztliche Gesprächsführung“ (22,98 ± 16,47% (Min. 0,00%; Max. 70,69%) von den Studierenden erreicht. Männer geben durchschnittlich an, mehr Lernziele erreicht zu haben als Frauen (9,84% vs. 8,22%; p=0.104731). Weiterhin haben Studierende, die ihr Praktikum in einem Lehrkrankenhaus mit weniger als 100 chirurgischen Bettenplätzen (10,60 ± 6,75%; Min. 2,33%; Max. 29,84%) oder in einer Rotation (9,95 ± 6,67%; Min. 1,90%; Max. 29,84%) durch mehrere Fachrichtungen absolvierten, angegeben mehr Lernziele erreicht zu haben als andere Studierende insgesamt.
Schlussfolgerung: Das zweiwöchige Blockpraktikum Chirurgie in Frankfurt kann den Studierenden (im Hinblick auf die Gesamtdauer des Medizinstudiums) einen großen Anteil der im NKLM formulierten Lernziele vermitteln. Vor allem die Lernziele der „Ärztlichen Rollen“ und der „klinisch-praktischen Fertigkeiten“ werden erlernt. Die Vermittlung gelingt besonders umfangreich in kleineren Lehrkrankenhäusern. Trotzdem bietet das Blockpraktikum Chirurgie den Teilnehmer nur einen kleinen Einblick in den Fachbereich Chirurgie. Für die Vermittlung von spezifischen chirurgischen Fähigkeiten, Prinzipen chirurgischer Diagnostik und Therapie, sowie Aspekte der „Patientenzentrierten Gesundheitsversorgung“ sind andere Formate notwendig.